INDV Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Indivior Pharmaceuticals, Inc (INDV) is not a strong buy at this moment for a beginner investor with a long-term strategy. While the company has shown strong financial growth in the latest quarter and has positive analyst sentiment, the technical indicators, options data, and recent market reactions suggest caution. The stock is currently trading in a neutral to slightly bearish trend, and the recent convertible notes offering has created market uncertainty. Waiting for clearer bullish signals or improved sentiment may be a better approach.
The MACD histogram is negative and expanding, indicating bearish momentum. RSI is neutral at 30.062, and moving averages are converging, showing no clear trend. The stock is trading close to its key support level of 30.034, with resistance at 34.572. Overall, the technical indicators suggest a neutral to slightly bearish trend.
Strong financial performance in Q3 2025, with revenue up 2.28% YoY and net income up 90.91% YoY.
Analyst upgrade from Northland with a price target raised to $50, citing strong fundamentals and capital allocation improvements.
Stock dropped 6% after the announcement of an upsized convertible notes offering, signaling market caution.
Gross margin dropped by 6.28% YoY, which could indicate operational challenges.
Technical indicators and pre-market price action suggest bearish momentum.
In Q3 2025, Indivior showed strong growth with revenue increasing by 2.28% YoY to $314 million, net income surging by 90.91% YoY to $42 million, and EPS growing by 94.12% YoY to 0.33. However, gross margin declined by 6.28% YoY to 73.57%, which could be a concern for long-term profitability.
Northland has raised its price target to $50 from $40 and maintained an Outperform rating, citing strong fundamentals and improved capital allocation. This reflects positive sentiment among analysts.
